drugset / Trial / NCT00597116

An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma

NCT00597116

Phase 2 Terminated 25 enrolled Genzyme, a Sanofi Company
RandomizedParallel-groupOpen-labelTreatment

Summary

A clinical study to assess if a new investigational drug is effective in treating malignant mesothelioma, compared to a chemotherapy treatment (Navelbine®). In this study the patients will be assigned by chance to receive either the new drug or a chemotherapy treatment (Navelbine®). Treatment will continue as long as the cancer does not worsen and the patient wishes to continue in the study. The study will recruit approximately 66 patients.

Timeline

Start
2007-12
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Vandetanib Small molecule Oral
Comparator Vinorelbine Small molecule